[1-(3,4-Dihydroxy-5-methyloxolan-2-yl)-5-fluoro-2-oxopyrimidin-4-yl] carbamate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: [1-(3,4-Dihydroxy-5-methyloxolan-2-yl)-5-fluoro-2-oxopyrimidin-4-yl] carbamate
• 英文别名: [1-(3,4-dihydroxy-5-methyloxolan-2-yl)-5-fluoro-2-oxopyrimidin-4-yl] carbamate
• 化学式: C₁₀H₁₂FN₃O₆
• 分子量: 289.22
• InChiKey: BESASEJKDQKIPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
  申请人：Ganymed Pharmaceuticals AG

  公开号：EP2976360A1

  公开（公告）日：2016-01-27
• [EN] THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIE UTILISANT DES ANTICORPS DIRIGÉS CONTRE LA CLAUDINE-18.2 POUR LE TRAITEMENT DU CANCER
  申请人：GANYMED PHARMACEUTICALS AG

  公开号：WO2014146778A1

  公开（公告）日：2014-09-25

  The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
• [EN] SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS<br/>[FR] STIMULATION SYNERGIQUE DE LA CYTOTOXICITÉ DU 5-FLUOROURACILE DANS DES CELLULES CANCÉREUSES PAR DES ANALOGUES DE DÉSOXYURIDINE
  申请人：STC UNM

  公开号：WO2015142867A1

  公开（公告）日：2015-09-24

  In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2'-deoxyuridine (fdU or foUdR) or a 5-formyl-2'-deoxyuridine derivative, optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5- fluoro-2'-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2'- deoxyuridine (FdU). Related pharmaceutical compositions are also provided.
• [EN] DRUG COMBINATIONS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND METHODS OF MAKING AND USING THEM<br/>[FR] COMBINAISONS DE MÉDICAMENTS AVEC DES MODULATEURS DE RÉCEPTEUR D'ANDROGÈNE SÉLECTIFS (SARM), ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：VICUS THERAPEUTICS LLC

  公开号：WO2016061135A1

  公开（公告）日：2016-04-21

  In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising drug combinations including a selective androgen receptor modulator (SARM), e.g., such as enobosarm or andarine, with one or more additional drugs or active agents, and methods for making and using them for treating, ameliorating, reversing or preventing a cancer such as a breast cancer, a basal-like carcinoma, a ductal carcinoma or an ovarian cancer, a tumor, a burn or a short stature or related syndrome or condition.